XTL Biopharmaceuticals Ltd.
XTLB
$1.25
-$0.08-6.02%
NASDAQ
| 12/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 279.90% | -11.42% | -27.86% | -16.04% | -2.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 508.50% | -11.11% | -25.98% | -19.31% | 0.80% |
| Operating Income | -306.00% | 11.11% | 25.98% | 19.31% | -0.80% |
| Income Before Tax | -35.56% | 62.03% | 73.81% | -27.72% | -281.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.21% | 62.03% | 73.81% | -27.72% | -281.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.21% | 62.03% | 73.81% | -27.72% | -281.62% |
| EBIT | -306.00% | 11.11% | 25.98% | 19.31% | -0.80% |
| EBITDA | -281.53% | 11.12% | 26.01% | 19.33% | -0.80% |
| EPS Basic | 40.00% | 64.29% | 73.33% | -40.00% | -288.89% |
| Normalized Basic EPS | -200.00% | 0.00% | -- | -- | -- |
| EPS Diluted | -50.00% | 57.14% | 60.00% | -40.00% | -288.89% |
| Normalized Diluted EPS | -200.00% | 0.00% | -- | -- | -- |
| Average Basic Shares Outstanding | 62.17% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 62.17% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |